» Authors » Rocio Villena-Gutierrez

Rocio Villena-Gutierrez

Explore the profile of Rocio Villena-Gutierrez including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 339
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Takaoka M, Tadross J, Al-Hadithi A, Zhao X, Villena-Gutierrez R, Tromp J, et al.
Cardiovasc Res . 2024 Sep; 120(17):2249-2260. PMID: 39312445
Aims: Heart failure and associated cachexia is an unresolved and important problem. This study aimed to determine the factors that contribute to cardiac cachexia in a new model of heart...
2.
Fernandez-Tocino M, Pun-Garcia A, Gomez M, Clemente-Moragon A, Oliver E, Villena-Gutierrez R, et al.
Basic Res Cardiol . 2024 Aug; 119(5):773-794. PMID: 39134663
β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia-reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this...
3.
Diaz-Guerra A, Villena-Gutierrez R, Clemente-Moragon A, Gomez M, Oliver E, Fernandez-Tocino M, et al.
JACC CardioOncol . 2024 May; 6(2):217-232. PMID: 38774018
Background: Anthracycline-induced cardiotoxicity (AIC) debilitates quality of life in cancer survivors. Serial characterizations are lacking of the molecular processes occurring with AIC. Objectives: The aim of this study was to...
4.
Pun-Garcia A, Clemente-Moragon A, Villena-Gutierrez R, Gomez M, Sanz-Rosa D, Diaz-Guerra A, et al.
Basic Res Cardiol . 2022 Nov; 117(1):62. PMID: 36445563
Aortic stenosis (AS) is associated with left ventricular (LV) hypertrophy and heart failure (HF). There is a lack of therapies able to prevent/revert AS-induced HF. Beta3 adrenergic receptor (β3AR) signaling...
5.
Ibanez B, Villena-Gutierrez R
J Am Coll Cardiol . 2021 Feb; 77(8):1089-1092. PMID: 33632483
No abstract available.
6.
Galan-Arriola C, Vilchez-Tschischke J, Lobo M, Lopez G, de Molina-Iracheta A, Perez-Martinez C, et al.
Cardiovasc Res . 2021 Feb; 118(2):531-541. PMID: 33605403
Aims: The aim of this study was to study changes in coronary microcirculation status during and after several cycles of anthracycline treatment. Methods And Results: Large-white male pigs (n=40) were...
7.
Clemente-Moragon A, Gomez M, Villena-Gutierrez R, Lalama D, Garcia-Prieto J, Martinez F, et al.
Eur Heart J . 2020 Oct; 41(46):4425-4440. PMID: 33026079
Aims: Clinical guidelines recommend early intravenous β-blockers during ongoing myocardial infarction; however, it is unknown whether all β-blockers exert a similar cardioprotective effect. We experimentally compared three clinically approved intravenous...
8.
Galan-Arriola C, Villena-Gutierrez R, Higuero-Verdejo M, Diaz-Rengifo I, Pizarro G, Lopez G, et al.
Cardiovasc Res . 2020 Jun; 117(4):1132-1143. PMID: 32597960
Aims: Anthracycline-induced cardiotoxicity (AIC) is a serious adverse effect among cancer patients. A central mechanism of AIC is irreversible mitochondrial damage. Despite major efforts, there are currently no effective therapies...
9.
Martinez-Milla J, Galan-Arriola C, Carnero M, Cobiella J, Perez-Camargo D, Bautista-Hernandez V, et al.
Basic Res Cardiol . 2020 Apr; 115(3):33. PMID: 32291522
Nonrevascularizable coronary artery disease is a frequent cause of hibernating myocardium leading to heart failure (HF). Currently, there is a paucity of therapeutic options for patients with this condition. There...
10.
Galan-Arriola C, Lobo M, Vilchez-Tschischke J, Lopez G, de Molina-Iracheta A, Perez-Martinez C, et al.
J Am Coll Cardiol . 2019 Feb; 73(7):779-791. PMID: 30784671
Background: Anthracycline-induced cardiotoxicity is a major clinical problem, and early cardiotoxicity markers are needed. Objectives: The purpose of this study was to identify early doxorubicin-induced cardiotoxicity by serial multiparametric cardiac...